<i>ADAR</i> Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy
Interferon (IFN)-β is the first-line disease management choice in multiple sclerosis (MS) with profound effects; however, in up to 50% of patients, clinical response does not occur. Ascertaining the responding state, need a long-term clinical follow-up, and this may lead to delay in use of other eff...
Main Authors: | Fakhr Fakhr, Shaygannejad Shaygannejad, Khorrami Khorrami, Saberi Saberi, Mirmosayyeb Mirmosayyeb, Sadeghi Sadeghi, Kheirollahi Kheirollahi |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2023-09-01
|
Series: | Global Medical Genetics |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1771001 |
Similar Items
-
The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis
by: Naeim Ehtesham, et al.
Published: (2016-11-01) -
Ischemic Strokes in a Young Woman With Manifestations of Multiple Sclerosis
by: Mohsen Janghorbani, et al.
Published: (2018-11-01) -
ADAR1 promotes systemic sclerosis via modulating classic macrophage activation
by: Chenming Sun, et al.
Published: (2022-12-01) -
Psychometric properties of the persian version of the multiple sclerosis work difficulties questionnaire (MSWDQ) questionnaire
by: Omid Mirmosayyeb, et al.
Published: (2022-01-01) -
Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
by: Saeed Vaheb, et al.
Published: (2023-04-01)